Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population

Milena M. McLaughlin; Audrey Galal; Chad L. Richardson; Sarah H. Sutton; Viktorija O. Barr; Niketa Patel; Porntiwa Mitchell; Valentina Stosor

doi:10.1111/tid.12769

Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population

Milena M. McLaughlin^*, Audrey Galal, Chad L. Richardson, Sarah H. Sutton, Viktorija O. Barr, Niketa Patel, Porntiwa Mitchell, Valentina Stosor

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Kidney transplant recipients who are switched to atovaquone (ATO) from trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis because of adverse events or complications may miss opportunities to be re-challenged with TMP/SMX, the first-line agent. This single-site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP/SMX to alternate PJP prophylaxis and outcomes of TMP/SMX re-challenge. Out of 166 patients, 155 initially received TMP/SMX; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re-challenged with TMP/SMX; all were successfully re-initiated on TMP/SMX therapy. Most patients switched to ATO post kidney transplant secondary to non-hypersensitivity reasons should be re-challenged with TMP/SMX because of the advantages it provides over other agents.

Original language	English (US)
Article number	e12769
Journal	Transplant Infectious Disease
Volume	19
Issue number	6
DOIs	https://doi.org/10.1111/tid.12769
State	Published - Dec 2017

Keywords

Pneumocystis jirovecii pneumonia (PJP)
atovaquone
kidney transplant
prophylaxis
trimethoprim-sulfamethoxazole

ASJC Scopus subject areas

Transplantation
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/tid.12769

Cite this

@article{3aa30eb6be954245a33fa082f71fb238,

title = "Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population",

abstract = "Kidney transplant recipients who are switched to atovaquone (ATO) from trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis because of adverse events or complications may miss opportunities to be re-challenged with TMP/SMX, the first-line agent. This single-site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP/SMX to alternate PJP prophylaxis and outcomes of TMP/SMX re-challenge. Out of 166 patients, 155 initially received TMP/SMX; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re-challenged with TMP/SMX; all were successfully re-initiated on TMP/SMX therapy. Most patients switched to ATO post kidney transplant secondary to non-hypersensitivity reasons should be re-challenged with TMP/SMX because of the advantages it provides over other agents.",

keywords = "Pneumocystis jirovecii pneumonia (PJP), atovaquone, kidney transplant, prophylaxis, trimethoprim-sulfamethoxazole",

author = "McLaughlin, {Milena M.} and Audrey Galal and Richardson, {Chad L.} and Sutton, {Sarah H.} and Barr, {Viktorija O.} and Niketa Patel and Porntiwa Mitchell and Valentina Stosor",

note = "Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = dec,

doi = "10.1111/tid.12769",

language = "English (US)",

volume = "19",

journal = "Transplant Infectious Disease",

issn = "1398-2273",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population

AU - McLaughlin, Milena M.

AU - Galal, Audrey

AU - Richardson, Chad L.

AU - Sutton, Sarah H.

AU - Barr, Viktorija O.

AU - Patel, Niketa

AU - Mitchell, Porntiwa

AU - Stosor, Valentina

PY - 2017/12

Y1 - 2017/12

N2 - Kidney transplant recipients who are switched to atovaquone (ATO) from trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis because of adverse events or complications may miss opportunities to be re-challenged with TMP/SMX, the first-line agent. This single-site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP/SMX to alternate PJP prophylaxis and outcomes of TMP/SMX re-challenge. Out of 166 patients, 155 initially received TMP/SMX; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re-challenged with TMP/SMX; all were successfully re-initiated on TMP/SMX therapy. Most patients switched to ATO post kidney transplant secondary to non-hypersensitivity reasons should be re-challenged with TMP/SMX because of the advantages it provides over other agents.

AB - Kidney transplant recipients who are switched to atovaquone (ATO) from trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis because of adverse events or complications may miss opportunities to be re-challenged with TMP/SMX, the first-line agent. This single-site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP/SMX to alternate PJP prophylaxis and outcomes of TMP/SMX re-challenge. Out of 166 patients, 155 initially received TMP/SMX; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re-challenged with TMP/SMX; all were successfully re-initiated on TMP/SMX therapy. Most patients switched to ATO post kidney transplant secondary to non-hypersensitivity reasons should be re-challenged with TMP/SMX because of the advantages it provides over other agents.

KW - Pneumocystis jirovecii pneumonia (PJP)

KW - atovaquone

KW - kidney transplant

KW - prophylaxis

KW - trimethoprim-sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=85032187337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032187337&partnerID=8YFLogxK

U2 - 10.1111/tid.12769

DO - 10.1111/tid.12769

M3 - Article

C2 - 28833985

AN - SCOPUS:85032187337

SN - 1398-2273

VL - 19

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

IS - 6

M1 - e12769

ER -

Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this